Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This investigation was designed to examine the contribution of
glucagon
to the regulation of free fatty acid (FFA) metabolism in man. The acute effects of exogenous
glucagon
upon the concentration of plasma FFA and its metabolites: acetoacetic acid (AcAc), beta hydroxybutyric acid (
BOH
), and triglyceride (TG) were assessed in five normal male subjects. The threshold of response was determined by administering intravenous
glucagon
in a graded dose-response fashion, andassessing the magnitude of change in FFA and its metabolites. A prompt rise in FFA concentration occurred after
glucagon
injection, and was associated with a synchronous elevation in both AcAc and
BOH
concentration in plasma. The rise in FFA concentration was maximal with the
glucagon
dosage of 0.5 mug./kg. with no greater FFA response seen athigher hormone dosage. In contrast, the rise in plasma ketones was linearly related to thedosage of
glucagon
but not to the corresponding rise in FFA concentration. The behavior of plasma triglyceride concentration following
glucagon
challenge also contrasted with the linear rise in ketone concentration. At the lowest dosage of
glucagon
, TG concentration rose transiently, while at the highest two dosages the concentration of TG was reduced. The transitional dosage of hormone at which no change in TG concentration was observed was approximately 0.5 mug./kg. Comparing our in vivo data with the conclusions reached from published liver perfusion studies, it can be suggested that in the dosages employed,
glucagon
acutely elevates plasma FFA concentration and modulates their metabolism by augmenting conversion to AcAc and
BOH
while tending to reduce conversion to TG in man.
...
PMID:Modulation of fatty acid metabolism by glucagon in man. I. Effects in normal subjects. 112 91